Email Updates

Search form

You are here

PrEP

Oral tenofovir-based PrEP works. Faster, smarter rollout must be a top priority.

Recent clinical trials have shown clearly that daily, oral pre-exposure prophylaxis (PrEP) using the antiretroviral drugs tenofovir and emtricitabine dramatically reduces the risk of HIV infection for men and women who take it as directed. While PrEP won’t be right for every individual at risk for HIV, untold numbers of men and women will benefit—if they can access this potentially life-saving option.

So far, PrEP’s implementation has been piecemeal and incomplete. TDF/FTC is approved for use as oral PrEP in a handful of countries but, for maximum impact, PrEP rollout needs a coherent, global strategy involving many real-world demonstration projects, other research and guidance from global health agencies. At the same time, research into new PrEP formulations—such as intermittent use of pills or quarterly injections—could help improve adherence and achieve PrEP’s full potential.

What We're Reading

In the space of 12 months, the number of gay men in London diagnosed with HIV dropped by 40 percent. The man credited as being at the center of this unprecedented reduction is Greg Owen—unemployed, a former sex worker and homeless. This Buzzfeed News piece tells his remarkable story.

February 25, 2017
BuzzFeed News

This aidsmap story covers a study that suggests increasing rates of sexually transmitted infections cannot easily be linked to PrEP. The study was presented in February at CROI.

February 22, 2017
aidsmap

Aidsmap reporter Gus Cairns takes a close look at the unusual first case of non-resistant HIV acquisition while adhering to PrEP.

February 17, 2017
aidsmap
Subscribe to RSS - PrEP